Next step for Xenome
Thursday, 25 September, 2008
Privately held biotech Xenome has begun a Phase II trial of lead candidate Xen2174 for the control of acute post-operative pain.
The trial will enrol approximately 200 patients at multiple clinical sites in the US.
The aim is to evaluate the safety and efficacy of Xen2174 administered as a single intrathecal administration to patients undergoing unilateral bunionectomy, a standard model for the assessment of acute pain therapies.
Xenome is also in Phase II trials of Xen2174 for chronic pain.
Researchers genetically engineer snake antivenom
An international team of researchers has used genetic engineering to create so-called...
Common medications linked to adverse breast cancer outcomes
An international study has found concerning evidence about the impact of a range of common...
Saliva-based biosensor could improve heart failure detection
Scientists have created a biosensor that can rapidly detect the heart failure biomarker S100A7 in...
